Evidence map›Paper›PMID 35222564›Full record

ArticleAfrican health sciences2021

Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected Cohort.

Isaac O Abah, Wetkos D Dayom, Dauda A Dangiwa, Roseline Aderemi-Williams, Joseph Anejo-Okopi, Oche O Agbaji, Phyllis Kanki, John C Aguiyi

Open access · diamondAbstract read
In one paragraph

Article in African health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Kaempferol fromToxicology reports · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Isaac O AbahDepartment of Clinical Pharmacy and Pharmacy Practice, Jos University Teaching Hospital/University of Jos, Jos, Nigeria.
Wetkos D DayomDepartment of Clinical Pharmacy and Pharmacy Practice, Jos University Teaching Hospital/University of Jos, Jos, Nigeria.
Dauda A DangiwaDepartment of Clinical Pharmacy and Pharmacy Practice, Jos University Teaching Hospital/University of Jos, Jos, Nigeria.
Roseline Aderemi-WilliamsDepartment of Clinical Pharmacy & Biopharmacy, Faculty of Pharmacy, University of Lagos, Idiaraba Campus, Lagos, Nigeria.
Joseph Anejo-OkopiDepartment of Microbiology, University of Jos, Jos, Nigeria.
Oche O AgbajiDepartment of Medicine, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
Phyllis KankiDepartment of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
John C AguiyiAfrican Centre of Excellence for Phytomedicine Research and Development University of Jos, Jos, Nigeria.
Jos University Teaching Hospital · NGUniversity of Jos · NGHarvard University · USUniversity of Lagos · NG

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
FIC NIH HHS D43 TW010543
6 · The paper itself

Abstract

backgroundDespite close to two decades of antiretroviral therapy (ART) in Nigeria, data on late on-onset ART-associated adverse drug reactions (ADRs) are sparse.

objectivesTo describe early and late-onset ADRs and compare their incidence in an outpatient HIV positive Cohort on ART.

methodWe described the incidence of clinical ADRs identified and documented in an outpatient clinic cohort of HIV-positive patients treated between June 2004 and December 2015 at a tertiary health facility in Nigeria. Incidence rates of ADRs during the first and subsequent years of ART were compared.

resultsof the 13,983 patients' data analyzed, 9317 were females (66%), and those in the age bracket of 25 to 45 years made up 78% of the studied population. During 52,411 person-years (py) of ART, 1485 incident ADRs were recorded; Incidence rate (IR) 28.3 (95% confidence interval [CI] 26.9:29.8) ADRs per 1000 person-years (py) of ART. The IR of ADRs was about two times higher in the first year of ART compared to subsequent years of treatment; crude incidence rate ratio (IRR) 1.77 (95% CI 1.59:1.97). Anemia, hypersensitivity reactions, and nervous system disorders had 7, 23, and 5 times higher incidence, respectively, in the first year of therapy, compared to subsequent years.

conclusionThe first year of ART is the period of highest risk of ADRs. Individual and programmatic treatment success in resource-limited settings requires strategies for early identification and management of ADR during the period of greatest risk of ADRs.

Indexed as

Drug-Related Side Effects and Adverse ReactionsHIV InfectionsAdultCohort StudiesFemaleHumansIncidenceMiddle AgedNigeriaAdverse drug eventsantiretroviral therapydrug toxicitysub Saharan Africa

Identifiers

PMID35222564
PMCPMC8843256
OpenAlexW3203583090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.